Skip to main content

Key new drugs help close out 2024

New biologics for breast cancer, hemophilia, and a rare form of heart disease are poised to add competition and choice in these classes.

Welcome to the Fall 2024 Notable New Drugs Report

New treatments target relatively small, hard-to-treat patient populations with big drug spend.

This edition of the report showcases:

  • A first-in-class treatment for both A and B hemophilia which can reduce the frequency of bleeding episodes.
  • A new addition to standard breast cancer therapy with improved outcomes for people with HR-positive breast cancer.
  • A new drug to treat a rare congenital heart disease can reduce the risk of death by 57%.

Don't want to read the full report? Download the summary.

Related healthcare insights

View all

Guide

Health Access Vision into Action Report

Learn how identifying and addressing disparities in healthcare allows everyone to live their healthiest life.

Article

Small price hikes make for big drug prices

We know about the high prices for new drugs, but drug companies make most of their money from repeated small price increases on older drugs.

Report

Regulations to watch: Spring 2025

Learn what’s at stake for pharmacy benefits sponsors as federal oversight changes and state legislative sessions begin.